Peroxisome proliferator-activated receptor-α is renoprotective in doxorubicin-induced glomerular injury

Kidney International

Volumn 79, Issue 12, 2011, Pages 1302-1311

  Zhou, Yunfeng ^a   Kong, Xiaomu ^a   Zhao, Pan ^a   Yang, Hang ^a   Chen, Lihong ^a   Miao, Jing ^b   Zhang, Xiaoyan ^a   Yang, Jichun ^a   Ding, Jie ^b   Guan, Youfei ^a  

^a PEKING UNIVERSITY HEALTH SCIENCE CENTER   (China)

^b PEKING UNIVERSITY FIRST HOSPITAL   (China)

Author keywords

doxorubicin; fenofibrate; peroxisome proliferator activated receptor; podocyte injury; proteinuria

Indexed keywords

CASPASE 3; CHOLESTEROL; CREATININE; CYTOCHROME P450 4A; CYTOCHROME P450 4A10; CYTOCHROME P450 4A14; DOXORUBICIN; FENOFIBRATE; KIDNEY INJURY MOLECULE 1; NEPHRIN; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR AGONIST; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR ALPHA; PROTEIN BAX; PROTEIN BCL 2; REACTIVE OXYGEN METABOLITE; SERUM ALBUMIN; TRIACYLGLYCEROL; UNCLASSIFIED DRUG; UREA;

ALBUMIN BLOOD LEVEL; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; APOPTOSIS; ARTICLE; BODY FAT; BODY WEIGHT; CHOLESTEROL BLOOD LEVEL; CONTROLLED STUDY; CREATININE BLOOD LEVEL; DISEASE SEVERITY; DOXORUBICIN INDUCED NEPHROPATHY; DRUG INDUCED DISEASE; GENE DELETION; GENE EXPRESSION; GENETIC TRANSCRIPTION; GLOMERULOPATHY; GLOMERULOSCLEROSIS; IN VITRO STUDY; IN VIVO STUDY; KIDNEY CELL CULTURE; KIDNEY FIBROSIS; KIDNEY MASS; KNOCKOUT MOUSE; LIVER WEIGHT; MALE; MESANGIUM CELL; MOUSE; NEPHROTOXICITY; NONHUMAN; PODOCYTE; PRIORITY JOURNAL; PROTEIN CLEAVAGE; PROTEIN EXPRESSION; PROTEIN URINE LEVEL; PROTEINURIA; RENAL PROTECTION; TRIACYLGLYCEROL BLOOD LEVEL; TUBULOINTERSTITIAL FIBROSIS; UREA NITROGEN BLOOD LEVEL;

EID: 79957815267     PISSN: 00852538     EISSN: 15231755     Source Type: Journal    
DOI: 10.1038/ki.2011.17     Document Type: Article

References (35)

1. Cheng H, Wang S, Jo YI et al. Overexpression of cyclooxygenase-2 predisposes to podocyte injury. J Am Soc Nephrol 2007; 18: 551-559. (Pubitemid 46193320)
2. Koshikawa M, Mukoyama M, Mori K et al. Role of p38 mitogen-activated protein kinase activation in podocyte injury and proteinuria in experimental nephrotic syndrome. J Am Soc Nephrol 2005; 16: 2690-2701.
3. Guo J, Ananthakrishnan R, Qu W et al. RAGE mediates podocyte injury in adriamycin-induced glomerulosclerosis. J Am Soc Nephrol 2008; 19: 961-972.
4. Vogtlander NP, Tamboer WP, Bakker MA et al. Reactive oxygen species deglycosilate glomerular alpha-dystroglycan. Kidney Int 2006; 69: 1526-1534.
5. Pippin JW, Brinkkoetter PT, Cormack-Aboud FC et al. Inducible rodent models of acquired podocyte diseases. Am J Physiol Renal Physiol 2009; 269: F213-229.
6. Guan Y. Peroxisome proliferator-activated receptor family and its relationship to renal complications of the metabolic syndrome. J Am Soc Nephrol 2004; 15: 2801-2815. (Pubitemid 41103389)
7. Auboeuf D, Rieusset J, Fajas L et al. Tissue distribution and quantification of the expression of mRNAs of peroxisome proliferator-activated receptors and liver X receptor-alpha in humans: no alteration in adipose tissue of obese and NIDDM patients. Diabetes 1997; 46: 1319-1327.
8. Guan Y, Breyer MD. Peroxisome proliferator-activated receptors (PPARs): novel therapeutic targets in renal disease. Kidney Int 2001; 60: 14-30. (Pubitemid 32587535)
9. Guan Y, Zhang Y, Davis L et al. Expression of peroxisome proliferatoractivated receptors in urinary tract of rabbits and humans. Am J Physiol 1997; 273: F1013-1022.
10. Portilla D. Energy metabolism and cytotoxicity. Semin Nephrol 2003; 23: 432-438. (Pubitemid 37176688)
11. Duval C, Chinetti G, Trottein F et al. The role of PPARs in atherosclerosis. Trends Mol Med 2002; 8: 422-430. (Pubitemid 34975988)
12. Park CW, Kim HW, Ko SH et al. Accelerated diabetic nephropathy in mice lacking the peroxisome proliferator-activated receptor alpha. Diabetes 2006; 55: 885-893.
13. Park CW, Zhang Y, Zhang X et al. PPARalpha agonist fenofibrate improves diabetic nephropathy in db/db mice. Kidney Int 2006; 69: 1511-1517.
14. Ruan X, Zheng F, Guan Y. PPARs and the kidney in metabolic syndrome. Am J Physiol Renal Physiol 2008; 294: F1032-F1047.
15. Nagothu KK, Bhatt R, Kaushal GP et al. Fibrate prevents cisplatin-induced proximal tubule cell death. Kidney Int 2005; 68: 2680-2693. (Pubitemid 43251013)
16. Lin H, Hou CC, Cheng CF et al. Peroxisomal proliferator-activated receptor-alpha protects renal tubular cells from doxorubicin-induced apoptosis. Mol Pharmacol 2007; 72: 1238-1245. (Pubitemid 350017443)
17. Li S, Basnakian A, Bhatt R et al. PPAR-alpha ligand ameliorates acute renal failure by reducing cisplatin-induced increased expression of renal endonuclease G. Am J Physiol Renal Physiol 2004; 287: F990-F998. (Pubitemid 39391096)
18. Li S, Wu P, Yarlagadda P et al. PPAR alpha ligand protects during cisplatininduced acute renal failure by preventing inhibition of renal FAO and PDC activity. Am J Physiol Renal Physiol 2004; 286: F572-F580. (Pubitemid 38233652)
19. Li S, Gokden N, Okusa MD et al. Anti-inflammatory effect of fibrate protects from cisplatin-induced ARF. Am J Physiol Renal Physiol 2005; 289: F469-F480. (Pubitemid 41003677)
20. Kamijo Y, Hora K, Kono K et al. PPARalpha protects proximal tubular cells from acute fatty acid toxicity. J Am Soc Nephrol 2007; 18: 3089-3100. (Pubitemid 350223969)
21. Fried LF, Orchard TJ, Kasiske BL. Effect of lipid reduction on the progression of renal disease: a meta-analysis. Kidney Int 2001; 59: 260-269. (Pubitemid 32055234)
22. Kim H, Haluzik M, Asghar Z et al. Peroxisome proliferator-activated receptor-alpha agonist treatment in a transgenic model of type 2 diabetes reverses the lipotoxic state and improves glucose homeostasis. Diabetes 2003; 52: 1770-1778. (Pubitemid 36792469)
23. Smulders YM, van Eeden AE, Stehouwer CD et al. Can reduction in hypertriglyceridaemia slow progression of microalbuminuria in patients with non-insulin-dependent diabetes mellitus? Eur J Clin Invest 1997; 27: 997-1002##1997. (Pubitemid 28012621)
24. Negishi K, Noiri E, Maeda R et al. Renal L-type fatty acid-binding protein mediates the bezafibrate reduction of cisplatin-induced acute kidney injury. Kidney Int 2008; 73: 1374-1384. (Pubitemid 351770480)
25. Ren S, Xin C, Beck KF et al. PPARalpha activation upregulates nephrin expression in human embryonic kidney epithelial cells and podocytes by a dual mechanism. Biochem Biophys Res Commun 2005; 338: 1818-1824. (Pubitemid 41643096)
26. Vielhauer V, Berning E, Eis V et al. CCR1 blockade reduces interstitial inflammation and fibrosis in mice with glomerulosclerosis and nephrotic syndrome. Kidney Int 2004; 66: 2264-2278. (Pubitemid 41115289)
27. Wang Y, Wang YP, Tay YC et al. Progressive adriamycin nephropathy in mice: sequence of histologic and immunohistochemical events. Kidney Int 2000; 58: 1797-1804.
28. Okuda S, Oh Y, Tsuruda H et al. Adriamycin-induced nephropathy as a model of chronic progressive glomerular disease. Kidney Int 1986; 29: 502-510. (Pubitemid 16129061)
29. Boonsanit D, Kanchanapangka S, Buranakarl C. L-carnitine ameliorates doxorubicin-induced nephrotic syndrome in rats. Nephrology (Carlton) 2006; 11: 313-320. (Pubitemid 44086876)
30. Zhou Y, Zhang X, Chen L et al. Expression profiling of hepatic genes associated with lipid metabolism in nephrotic rats. Am J Physiol Renal Physiol 2008; 295: F662-F671.
31. Ruan XZ, Varghese Z, Moorhead JF. An update on the lipid nephrotoxicity hypothesis. Nat Rev Nephrol 2009; 5: 713-721.
32. Bobulescu IA. Renal lipid metabolism and lipotoxicity. Curr Opin Nephrol Hypertens 2010; 19: 393-402.
33. van den Berg JG, van den Bergh Weerman MA, Assmann KJ et al. Podocyte foot process effacement is not correlated with the level of proteinuria in human glomerulopathies. Kidney Int 2004; 66: 1901-1906.
34. Mundel P, Reiser J, Zuniga Mejia Borja A et al. Rearrangements of the cytoskeleton and cell contacts induce process formation during differentiation of conditionally immortalized mouse podocyte cell lines. Exp Cell Res 1997; 236: 248-258. (Pubitemid 27452369)
35. Zheng F, Fornoni A, Elliot SJ et al. Upregulation of type I collagen by TGF-beta in mesangial cells is blocked by PPARgamma activation. Am J Physiol Renal Physiol 2002; 282: F639-F648. (Pubitemid 34654511)